| Name | Dihydroisotanshinone I |
| Description | Dihydroisotanshinone I is a natural product isolated from the dried roots of Salvia miltiorrhiza, a traditional Chinese medicine, and exhibits various biological activities. Dihydroisotanshinone I alleviates menadione-induced liver injury through antioxidant effects such as scavenging free radicals and inhibiting lipid peroxidation; it also inhibits the migration of prostate cancer cells and induces cancer cell apoptosis. |
| In vitro | Dihydroisotanshinone I induces cell cycle G1 arrest by inhibiting the expression of cyclin D1, cyclin E1, CDK2, CDK4, CDK6, p-Rb, E2F1 and SKP2, and suppresses the proliferation of human osteosarcoma 143B cells in a dose- and time-dependent manner.
Dihydroisotanshinone I induces apoptosis via activating caspase-3, caspase-8, caspase-9 and cleaving PARP, and inhibits cell migration by down-regulating VCAM-1 and ICAM-1. |
| In vivo | In xenograft tumor models, Dihydroisotanshinone I inhibits the proliferation of Hela human cervical cancer cells. It enhances radiation-induced apoptosis and significantly inhibits proliferation in Hela cells mainly by prolonging radiation-induced G2/M arrest and reducing the expression levels of Bcl-XL, Bcl-2 and HPV E6 protein. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 5.00 mg/mL (17.97 mM), Sonication is recommended.
|
| Keywords | PotassiumChannel | Potassium Channel | Dihydroisotanshinone I | CalciumChannel | Calcium Channel | ATPase |
| Inhibitors Related | Stavudine | Aceglutamide | Urea | Tamoxifen | Cysteamine hydrochloride | Metronidazole | Citric Acid Triammonium | Formamide | Dimethyl phthalate | Alginic acid | Sodium Molybdate | Sildenafil citrate |
United States
